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An abundant dysfunctional apolipoprotein A1
in human atheroma
Ying Huang, Joseph A DiDonato, Bruce S Levison, Dave Schmitt, Lin Li Yuping Wu, Jennifer Buffa,
Timothy Kim, Gary S Gerstenecker, Xiaodong Gu, Chandra S Kadiyala, Zeneng Wang, Miranda K Culley,
Jennie E Hazen, Anthony J DiDonato, Xiaoming Fu, Stela Z Berisha, Daoquan Peng, Truc T Nguyen,
Shaohong Liang, Chia-Chi Chuang, Leslie Cho, Edward F Plow, Paul L Fox, Valentin Gogonea,
W H Wilson Tang, John S Parks, Edward A Fisher, Jonathan D Smith, Stanley L Hazen
Recent studies have indicated that high-density lipoproteins (HDLs) and their major structural protein, apolipoprotein
A1 (apoA1), recovered from human atheroma are dysfunctional and are extensively oxidized by myeloperoxidase (MPO).
In vitro oxidation of either apoA1 or HDL particles by MPO impairs their cholesterol acceptor function. Here, using phage
display affinity maturation, we developed a high-affinity monoclonal antibody that specifically recognizes both apoA1 and
HDL that have been modified by the MPO-H2O2-Cl− system. An oxindolyl alanine (2-OH-Trp) moiety at Trp72 of apoA1 is
the immunogenic epitope. Mutagenesis studies confirmed a critical role for apoA1 Trp72 in MPO-mediated inhibition of the
ATP-binding cassette transporter A1 (ABCA1)-dependent cholesterol acceptor activity of apoA1 in vitro and in vivo. ApoA1
containing a 2-OH-Trp72 group (oxTrp72-apoA1) is in low abundance within the circulation but accounts for 20% of the apoA1
in atherosclerosis-laden arteries. OxTrp72-apoA1 recovered from human atheroma or plasma is lipid poor, virtually devoid of
cholesterol acceptor activity and demonstrated both a potent proinflammatory activity on endothelial cells and an impaired HDL
biogenesis activity in vivo. Elevated oxTrp72-apoA1 levels in subjects presenting to a cardiology clinic (n = 627) were associated
with increased cardiovascular disease risk. Circulating oxTrp72-apoA1 levels may serve as a way to monitor a proatherogenic
process in the artery wall.

HDL is a complex and heterogeneous assembly of proteins and lipids.
Defined by its buoyant density isolation characteristics, HDL’s compositional heterogeneity mirrors its functional heterogeneity, which
includes cholesterol acceptor activity, microRNA delivery and antiinflammatory, anti-apoptotic, anti-thrombotic and innate immune
functions1–6. Approximately 75% of the protein content of HDL is
apoA1, which serves as the primary protein scaffolding on which the
lipid cargo-carrying particle is built. The majority of apoA1 within
the circulation is associated with HDL particles, which contain two
or more apoA1 polypeptide chains, depending on both the degree of
particle maturation and the protein complement associated with a
given HDL particle. Epidemiological studies have shown an inverse
association between circulating HDL cholesterol (HDLc) or apoA1
levels and coronary artery disease (CAD) 7. Animal studies using
both genetic and direct infusion models have similarly shown global
anti-atherosclerotic functions of the lipoprotein8–12. Recent clinical
studies, however, have revealed gaps in our knowledge about HDL.
For example, whereas several clinical intervention studies employing
either direct infusion of HDL forms or infusion of extracorporeally

delipidated HDL or apoA1 have shown anti-atherosclerotic effects13–15,
several distinct classes of HDL cholesterol–elevating drugs have, in
contrast, failed to demonstrate significant therapeutic benefit16–18.
Moreover, Mendelian genetic studies have demonstrated that genetic
variants that influence total circulating HDLc levels are not mechanistically linked to the development of CAD19. Taken as a whole, recent
studies underscore the complexity and evolving understanding of the
relationship between circulating levels of HDLc and/or apoA1 and
CAD pathogenesis.
One possible explanation of the paradox between, on the one hand,
the well-established inverse association between HDLc levels and cardiovascular disease (CVD), and on the other, the negative outcomes of
recent therapeutic intervention studies raising HDLc levels, is that it is
HDL particle function, not HDLc mass, that is more clinically relevant
diagnostically and therapeutically. For example, measurement of the
cholesterol efflux activity of HDL, or of apoB-depleted serum, may serve
as a superior independent predictor of prevalent CAD risk compared
to HDLc4. Moreover, alternative functional measures of HDL or
its associated proteins may provide improved clinical value and

prognostic efficacy5,20–24. Accordingly, current measures of HDL
mass (either HDLc or apoA1) in the circulation do not appear to
adequately reflect the pathobiology of a diseased artery wall. Recent
studies of total apoA1 (both HDL-associated and lipid-poor forms)
from human aortic tissues revealed that the biological function and
HDL particle distribution of apoA1 within the artery wall are markedly distinct from those of circulating apoA1 and HDL. Specifically,
apoA1 in human aorta was found to be predominantly lipid poor,
not associated with HDL, extensively oxidatively crosslinked
and functionally impaired25. ApoA1 serves as a selective target
(100- to 500-fold relative to total protein) for oxidative modification by MPO-generated and nitric oxide–derived oxidants within
the artery wall, resulting in site-specific oxidative modifications26–28.
Parallel in vitro studies using HDL or apoA1 oxidized ex vivo by the
MPO-H2O2-Cl− system have shown marked reductions in their various activities—ABCA1-dependent cholesterol efflux function, lecithin cholesterol acyl transferase (LCAT) activity, lipid binding activity
and non–cholesterol related activities (for example, anti-apoptotic and
anti-inflammatory activities)—to an extent similar to that observed
for apoA1 recovered from human lesions26,28–30. These findings, as
well as studies demonstrating proinflammatory activities of HDL
recovered from subjects with CAD or chronic inflammatory conditions associated with CAD risk21,29,31–33, suggest that the molecular
processes that impair apoA1 and HDL function in the artery wall may
be diagnostic and therapeutic targets for CAD.
Here we report that Trp72 of apoA1 serves as a selective target
for MPO-dependent oxidative modification, forming an oxindolyl
alanine (2-hydroxy-l-tryptophan, or 2-OH-Trp; IUPAC name
2-amino-3-(2-oxo-1,3-dihydroindol-3-yl)propanoic acid) moiety
on 20% of apoA1 recovered from human atherosclerotic lesions.
We found that both lesion and plasma apoA1 harboring this sitespecific modification were dysfunctional, with significantly impaired
cholesterol efflux acceptor activity as well as proinflammatory effects.
Moreover, data from clinical studies indicate that circulating levels of
this dysfunctional apoA1 form reflect a pathophysiological process
within the artery wall.
RESULTS
Development of an antibody specific for MPO-modified apoA1
Direct studies of HDL function in the human artery wall have been
limited so far. To recover and study the chemical modifications and
biological activities of HDL modified by MPO-generated oxidants
in the artery wall, we developed immunological tools to specifically
detect and immunopurify apoA1 modified by the MPO-H 2O2-Cl−
system. We selected this specific oxidized form of apoA1 and HDL
because in vitro studies have demonstrated that this system readily
inhibits the cholesterol acceptor activity of both apoA1 and HDL
under pathophysiologically plausible conditions26,27,29. After immunizing BALB/c mice with native reconstituted HDL particles (apoA1:
POPC:cholesterol, 1:100:10, mol:mol:mol) exposed to either MPOgenerated chlorinating oxidants (the MPO-H2O2-Cl− system) or
MPO-generated nitrating oxidants (the MPO-H2O2-NO2− system),
we generated and screened over 30,000 hybridoma cell lines
(Supplementary Fig. 1a). To ensure that the epitopes formed would
be those likely to be formed under (patho)physiologically plausible
conditions, we used a low molar ratio of H2O2 to apoA1 (5:1); under
these conditions, the content of protein-bound 3-chlorotyrosine or
3-nitrotyrosine was within the range previously observed on apoA1
recovered from human atherosclerotic plaque26,29. We identified a
monoclonal antibody (mAb) (clone 8B5.2) that specifically recognized

both apoA1 and HDL exposed to the MPO-H2O2-Cl− system but not
apoA1 or HDL in their native (unoxidized) forms or after exposure to
alternative oxidant systems, including the MPO-H2O2-NO2− oxidant
system (Supplementary Fig. 1a).
Although mAb 8B5.2 had the desired specificity, its affinity was
too low for either efficient immunoprecipitation or use in an ELISA
format to detect endogenous circulating levels of oxTrp72-apoA1
(Supplementary Fig. 1b–d). We next used phage display technology
to affinity mature (as a single-chain antibody) mAb 8B5.2 and then,
after sequencing gain-of-function mutants, genetically engineered
the recombinant IgG form (Online Methods). Briefly, we used human
apoA1 exposed to the MPO-H2O2-Cl− system as the positive-selection
bait. After the first round of positive selection, we used as negative
selection baits both native human apoA1 and human apoA1 exposed
to MPO-generated nitrating oxidants (Online Methods). During the
last two affinity maturation cycles, we sequenced multiple gain-offunction subclones and identified reproducible gain-of-function
mutations. We then incorporated all gain-of-function mutants into a
single clone and verified it to be functional as a high-affinity binder
with the appropriate specificity. We then converted this ‘combined’
gain-of-function clone into a human-mouse chimeric IgG mAb
(Fig. 1a–c). We termed this affinity-matured recombinant humanized
mAb r8B5.2, which displayed a 1,600-fold enhanced affinity compared to the starting (parental) mAb, attaining a KD of 1 × 10−10 M
(Supplementary Fig. 1c). More detailed characterization studies
confirmed that mAb r8B5.2 retained exclusive specificity for recognition of apoA1 exposed to the MPO-H2O2-halide system (Fig. 1d).
Further characterization revealed that mAb r8B5.2 had sufficient
affinity to immunoprecipitate MPO-oxidized apoA1 and, when used
in an ELISA format, had adequate sensitivity to detect and quantify
apoA1 and HDL after oxidation by the MPO-H2O2-Cl− system at
levels of oxidation comparable to those observed in plasma or serum
(Supplementary Fig. 1d).
ApoA1 Trp72 oxidation inhibits cholesterol acceptor function
No studies to our knowledge have directly examined the functional
importance of modification of apoA1 or HDL by MPO within human
atheroma. Rather, the proposed in vivo effect of MPO-catalyzed
oxidation of apoA1 and HDL—impairing the cholesterol acceptor
activity of the lipoprotein—is based on correlative data that compare the degree of oxidative modifications on apoA1 recovered from
artery wall tissues with both the extent of oxidative modifications
formed and the degree of ABCA1-dependent cholesterol efflux
impairment observed in model systems ex vivo26,29. Incubation of
apoA1 or HDL with the MPO-H2O2-Cl− system can promote oxidative modification of multiple oxidant-sensitive residues of apoA1,
including (but not limited to) each of the three methionines, each
of the seven tyrosines and each of the four tryptophans. Oxidation
of each of these residues has been detected by proteomics analysis
of apoA1 or HDL recovered from human atherosclerotic lesions, yet
debate exists about the relative abundance of various species and
their functional importance26–29,34. We hypothesized that the epitope
recognized by mAb r8B5.2 might be an oxidized form of tyrosine,
methionine or tryptophan generated by the MPO-H2O2-Cl− system
within the appropriate sequence context of apoA1. To test this idea,
we generated recombinant mutant forms of apoA1 in which each of
these residues was converted to a relatively nonoxidizable alternative
amino acid of similar size and chemical properties, namely (i) each of
the seven tyrosine residues (positions 18, 29, 100, 115, 166, 192 and
236) was mutated to the relatively nonoxidizable phenylalanine
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residue (a mutant named 7YF); (ii) each of the three methionine
residues (positions 86, 112 and 148) was mutated to the relatively
nonoxidizable valine residue (a mutant named 3MV); and
(iii) each of the four tryptophan residues (positions 8, 50, 72 and 108)
was mutated to the relatively nonoxidizable phenylalanine residue
(a mutant named 4WF). We reasoned that after exposure of the
lipoprotein to the MPO-H2O2-Cl− system, the mutant form of apoA1
no longer harboring the oxidant-sensitive residue would not be
recognized by mAb r8B5.2, whereas recombinant human (wild-type
sequence) apoA1 (rh-apoA1) would be recognized after oxidation.
Exposure of rh-apoA1, 7YF and 3MV to the MPO-H2O2-Cl− system
produced an oxidized apolipoprotein that was recognized by mAb
r8B5.2, whereas the apoA1 mutant 4WF was not recognized after
oxidation (Fig. 2a). Notably, control studies showed that all mutant
forms of apoA1 examined retained cholesterol efflux activity in their
native forms, and all forms but 4WF lost ABCA1-dependent and total
cholesterol efflux activities after exposure to the MPO-H2O2-Cl−
system (Fig. 2b). Collectively, these results suggest that one or more of
the tryptophan residues of apoA1 contribute to formation of the epitope
recognized by mAb r8B5.2 after oxidation by the MPO-H2O2-Cl−
system. Moreover, these data indicate that one or more of the tryptophan residues functions as an oxidative switch for impairing the
cholesterol efflux activity of apoA1.
To identify the oxidized tryptophan residue that serves as the
epitope recognized by mAb r8B5.2, we generated additional sitespecific mutant forms of apoA1 in which each of the four tryptophan
residues was converted singly to leucine (W8L, W50L, W72L and
W108L). Alternatively, each of two of the residues was converted
singly to phenylalanine (W72F and W108F). The MPO-oxidized form
of each recombinant apoA1 mutant was recognized by the antibody
except for mutants with site-specific mutation of Trp72 (Fig. 2a).
Competition experiments using a molar excess of different oxidized
forms of tryptophan (as free amino acids) suggested that the oxygen at
the 2 position of the indole ring was important for epitope recognition
(Supplementary Fig. 2). We confirmed that a 2-oxindolyl alanine, the
2-OH-Trp moiety at Trp72 of apoA1 (oxTrp72-apoA1), is the recognition site for mAb r8B5.2 using two additional ELISA-based competition
experiments. In the first experiment, we used synthetic peptides containing the sequences in apoA1 that span each of the four tryptophan
residues, in which the peptide was either in its native form (with a Trp
residue) or in its oxidized form (with a 2-OH-Trp residue) (Fig. 2c).
In the second experiment, we used a peptide spanning Trp72 in which
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Figure 1 Phage display affinity maturation to form a high-affinity
mAb specific for apoA1 oxidized by the MPO-H2O2-halide system.
(a) Fold increase in apparent binding affinity after the indicated rounds
(1–4) of biopanning after phage display affinity maturation of the
parental mouse mAb 8B5.2 single-chain antibody (scFv). r8B5.2,
the recombinant affinity matured scFv antibody. (b) Complementaritydetermining region (CDR) DNA sequences of the original mAb 8B5.2 and
those of nine affinity-matured scFv r8B5.2 subclones identified
with lowest dissociation rate. CDRL1-3, CDRs of antibody light chain;
CDRH1-3, CDRs of antibody heavy chain. The letters indicate the
identities of the mutated amino acids and the differences between original
and affinity-matured clones. (c) The increase in apparent affinity (KD) of
the parental mAb 8B5.2 antibody and the affinity-matured scFv r8B5.2
antibody after conversion to a full-length mouse-human chimeric IgG1,
designated as r8B5.2. (d) ApoA1 or reconstituted HDL (rHDL) in native
form, or following exposure to the indicated oxidation systems, were
coated onto 96-well plates and detected with r8B5.2 (Online Methods).
OD, optical density; A450nm, absorbance at 450 nm; NA, no addition.
All data are shown as the mean ± s.d. of triplicate determinations.

Trp within the peptide was in its native form or in its 2-OH or 5-OH
indole–oxidized forms (Fig. 2d).
We next sought to determine the functional importance of Trp72
for the cholesterol acceptor activity of apoA1 in native and MPOoxidized conditions. Exposure of native recombinant human apoA1
to increasing levels of oxidation by the MPO-H2O2-Cl− system
at molar ratios of H2O2 to apoA1 of ~0–2 resulted in little loss of
ABCA1-dependent cholesterol efflux activity (Fig. 2e). Mass spectrometry studies detected methionine sulfoxide formation at each of
the three apoA1 methionine residues at these low levels of oxidation
(data not shown). However, with increasing molar ratios of H2O2 to
apoA1, there was an abrupt dose-dependent inhibition of ABCA1dependent cholesterol acceptor activity, with virtually no remaining
activity at a 10:1 molar ratio (Fig. 2e). This level of oxidant exposure is within the upper end of that observed within atherosclerotic
plaques, based on the protein-bound 3-chlorotyrosine content of
apoA1, as monitored by liquid chromatography tandem mass spectrometry (LC/MS/MS) analyses (Supplementary Fig. 1d). In contrast,
the 4WF apoA1 mutant was resistant to oxidative inactivation of
ABCA1-dependent cholesterol acceptor activity, with unaltered activity even in the presence of a 50-fold molar excess of oxidant relative
to apoA1 (Fig. 2e), a result that is consistent with previous reports28.
We next examined the effect of site-specific mutation of Trp72 to a
relatively oxidant-resistant hydrophobic residue (phenylalanine or
alanine). Either mutation resulted in an approximate 50% reduction in
ABCA1-dependent cholesterol efflux activity at a tenfold molar excess
of oxidant (Fig. 2e). Alternatively, apoA1 in which the other three
tryptophan residues of apoA1 were mutated to phenylalanine (the
3F72W mutant) showed a similar extent (~50%) of functional inactivation under the same oxidant conditions (Fig. 2e and Supplementary
Fig. 1d). Collectively these studies indicate that after exposure to the
MPO-H2O2-halide system, oxidation of Trp72 of apoA1, yielding a
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Figure 2 Epitope mapping of affinity-matured mAb r8B5.2. (a) Antibody (r8B5.2) reactivity against the
4WF
4
indicated recombinant human apoA1 (rh-apoA1) and mutant forms quantified before and after exposure
to the MPO-H2O2-halide system. (b) Total and ABCA1-dependent cholesterol efflux activities in RAW
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macrophages performed with rh-apoA1 and the indicated mutant apoA1 forms before or after exposure to
2
72WA
the MPO-H2O2-halide system (Online Methods). (c,d) Competitive ELISAs. Purified human apoA1 oxidized
rh-apoA1
by the MPO-H2O2-Cl− system served as the coating antigen. Antibody r8B5.2 binding was competed
0
for with increasing concentrations of the indicated (in bold) tryptophan-containing apoA1 competitor peptides
0
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incorporating either native (nonoxidized) tryptophan or 2-OH-Trp at the indicated positions in c. In d, the
H2O2/apoA1 molar ratio
indicated peptide used as a competitor harbored native tryptophan, 2-OH-Trp or 5-OH-Trp corresponding
to position 72. (e) Effect of tryptophan substitutions on rh-apoA1 ABCA1-dependent cellular cholesterol
efflux function. The indicated rh-apoA1 and mutant apoA1 proteins were exposed to the MPO-H 2O2-Cl− oxidation system at the specified molar ratios
of H2O2 to apoA1 (0 to 50:1, mol:mol). Proteins were assayed for ABCA1-dependent cellular cholesterol acceptor activity (Online Methods). All data
shown are the means ± s.d. of at least triplicate determinations.

2-oxindolyl alanine (2-OH-Trp) moiety, is specifically recognized
by mAb r8B5.2 (henceforth we refer to apoA1 detected by mAb r8B5.2
as oxTrp72-apoA1 to indicate the epitope recognized). Moreover,
oxidation of this residue is responsible for about 50% of the the loss
of cholesterol acceptor function of the oxidized lipoprotein.
Lesion apoA1 harbors a 2-OH-Trp72 group and is dysfunctional
Using this new immunological tool, we found by immunohistochemical staining that oxTrp72-apoA1 is present in human atherosclerotic
plaques but not in normal human aorta (Fig. 3a). Staining of arterial
tissues in parallel with an antibody to MPO revealed a staining
pattern within plaques that was similar overall to that observed with anti–
oxTrp72-apoA1. However, whereas oxTrp72-apoA1 was not detectable
in normal arterial tissue, we did detect weak MPO staining in this tissue, with staining along the endothelial surface, within endothelial cells
and in the narrow subendothelial space (Supplementary Fig. 3a,b).
To further characterize oxTrp72-apoA1 in human aortic plaque,
we performed an SDS-PAGE analysis of human aortic plaque
homogenate (n = 5 subjects). For this analysis, we used the low-speed
supernatant of the homogenate either before or after buoyant density
ultracentrifugation to separate a global lipoprotein fraction (density
(d) ≤ 1.21 g ml−1) from the lipoprotein-depleted (LPD) fraction
(d > 1.21 g ml−1) (Fig. 3b). Western blot analyses performed in
parallel using mAb r8B5.2 revealed that virtually all detectable
oxTrp72-apoA1 resided in a lipid-poor soluble form (i.e., a form that
was not lipoprotein associated) (Fig. 3c). More detailed quantification
showed that ~80% of oxTrp72-apoA1 within human aortic plaque
homogenate was recovered in the LPD fraction and <1% was
recovered within the lipoprotein-containing fraction (Fig. 3d).
We next studied the functional characteristics of oxTrp72-apoA1
recovered from human atherosclerotic plaques. We used an affinity
column with covalently linked mAb r8B5.2 to isolate an apoA1 form
harboring the 2-OH-Trp moiety at residue 72 (oxTrp72-apoA1) from
human artery lesion homogenates. Affinity-isolated oxTrp72-apoA1
analyzed by SDS-PAGE appeared to be at high purity: the major visible

bands were at the molecular weights anticipated for the apoA1 monomer and dimer (Fig. 3e). Mass spectrometry analyses directly detected
tryptic peptides containing oxTrp72 (OH) (Supplementary Fig. 3c),
and virtually no tryptic peptides harboring native (unoxidized) Trp72
were recovered. Furthermore, mass spectrometry analyses of excised
bands corresponding to the presumed monomer, dimer, trimer and
higher–molecular weight crosslinked forms of apoA1 revealed that
they all predominantly contained apoA1 (Supplementary Table 1a,b).
We next examined the cholesterol acceptor function of oxTrp72-apoA1
recovered from aortic lesions from multiple subjects (n = 6). Even at a
concentration (10 µg ml−1) that was twice that used for native human
apoA1 (used as the positive control), oxTrp72-apoA1 used as a cholesterol acceptor showed only negligible ABCA1-dependent cholesterol
efflux activity (Fig. 3f). Collectively, these results demonstrate that
oxTrp72-apoA1, an MPO-modified form of apoA1 present within
human atheroma, is predominantly non-HDL (lipoprotein) associated
and is dysfunctional with respect to cholesterol efflux activity.
Plasma oxTrp72-apoA1 is proinflammatory
To examine the distribution of oxTrp72-apoA1 in the circulation,
we fractionated plasma from multiple healthy subjects (six pooled
healthy donor pools, each pool was obtained from ≥ five subjects)
by buoyant density ultracentrifugation and determined the level of
oxTrp72-apoA1 within each fraction. Similarly to human atherosclerotic plaques, virtually all detectable oxTrp72-apoA1 in the plasma
resided in the LPD fraction (d > 1.21 g ml−1), with only nominal levels
recovered in the HDL fraction (d = 1.063–1.21 g ml−1) (Fig. 4a–c).
Because of the possibility that the high shear forces of ultracentrifugation might ‘knock off ’ oxTrp72-apoA1 from the HDL, we performed
additional studies to verify these findings. Using polyclonal antibodies
(anti-HDL IgY) raised in chickens against human HDL (isolated from
plasma of healthy volunteers) and covalently attached to resin, we
immunoisolated HDL from the plasma of ten healthy (>50 years of
age) subjects with no known CAD. Separate studies of the binding
characteristics of the anti-HDL IgY antibody revealed preferential
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Figure 3 Characterization of oxTrp72-apoA1
recovered from human atherosclerotic plaque.
(a) Immunohistochemical staining of fresh-frozen
normal and atherosclerotic sections of human
aorta. OxTrp72-apoA1 was detected with mAb
r8B5.2. Mouse IgG was used as the control.
Red, positive staining; blue, H&E counter stain.
(b,c) SDS-PAGE, protein (SYPRO ruby) staining
(b) and western blot analysis (c) of human aortic
plaque homogenate and the indicated fractions
separated by buoyant density ultracentrifugation.
(d) OxTrp72-apoA1 levels (as a percentage of
total apoA1) recovered in human atherosclerotic
tissue homogenate and in the lipoprotein
(d ≤ 1.21 g ml−1) and LPD (d > 1.21 g ml−1)
fractions. The data are shown as the means ± s.d.
of triplicate determinations of n = 4 subjects.
(e) SDS-PAGE followed by Coomassie
Blue (protein) staining of mAb r8B5.2–
immunopurified oxTrp72-apoA1 from human
aortic tissue (lane 2). As a positive control,
apoA1 exposed to the MPO-H2O2-Cl− system
(at a 10:1 molar ratio of H2O2 to apoA1;
Cl.apoA1), was loaded in lane 4. The ApoA1
monomer and dimer are indicated. MW,
molecular weight markers (lane 1);
IP, immunoprecipitation. Lane 3 is empty.
(f) ABCA1-dependent cholesterol efflux activity
of oxTrp72-apoA1 immunoaffinity purified
from individual (n = 6 subjects) human aortic
plaques. Each bar represents data from a
different subject’s sample. Native apoA1 and
Cl.apoA1 were used as controls. Results shown
are mean ± s.d. of triplicate determinations.
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from the plasma of each subject was confirmed by Coomassie Blue staining of native
gels (Supplementary Fig. 4a). Western blot analyses with mAb 10G1.5 (Supplementary Fig. 4d). No detectable light or heavy chain immuno
(termed anti-total apoA1), which recognizes equally well native and globulin contamination was observed under the conditions employed
oxidized forms of apoA1 and HDL25, confirmed the presence of (Supplementary Fig. 4d).
We and others have shown that HDL isolated from healthy volunapoA1 within the immunoaffinity-isolated material from each subject
(Supplementary Fig. 4b). In contrast, western blot analyses of native teers has anti-inflammatory effects when incubated with bovine aortic
gels using mAb r8B5.2 failed to detect any bands within the HDL endothelial cells, whereas apoA1 or HDL modified by MPO ex vivo confractions even with extensive overexposure (Supplementary Fig. 4c). verts the lipoprotein into a proinflammatory particle29. We therefore
However, mAb r8B5.2 did detect bands if used in western blot analy- examined the proinflammatory properties of oxTrp72-apoA1 recovses of the samples using SDS-PAGE and with extensive overexposure ered from the circulation of a nonoverlapping set of apparently healthy
(data not shown). Together, these results indicate that oxTrp72-apoA1, middle aged (>50 years of age) donors (n = 12). For comparison, we
although present within the circulation, does not reside on an HDL isolated total apoA1 from the same donors using polyclonal chicken
particle to any major extent, but rather is present as a low-abundance IgY antibodies raised against native human apoA1 (Fig. 4e). After
lipid-poor form of apoA1 in the LPD fraction.
incubation of oxTrp72-apoA1 recovered from each subject’s plasma
We next used mAb 8B5.2 to immunoaffinity isolate circulating with bovine aortic endothelial cells, we observed a marked proinflamoxTrp72-apoA1 from healthy subjects (multiple healthy donor pools, matory effect, as monitored by substantial increases in surface vascueach pool was obtained from ≥ five subjects) to characterize its biologi- lar cell adhesion molecule 1 (VCAM1) protein content. In contrast,
cal activity. By Coomassie Blue staining, the recovered protein appeared apoA1 recovered from plasma using immunoprecipitation with the
to be of high purity, with the major visible bands corresponding anti-HDL IgY antibodies, or a comparable amount of total plasma
to the apoA1 monomer and oxidative crosslinked dimer (Fig. 4d). By protein, did not elicit a proinflammatory response in the endothemass spectrometry analyses the recovered bands were confirmed to lial cells (Fig. 4e). Moreover, immuno-isolated lipid-free (i.e., after
be apoA1, with multiple peptides containing oxidized residues (pre- organic solvent extraction) oxTrp72-apoA1 recovered from plasma
dominantly tryptophan and methionine; Supplementary Table 1c). promoted endothelial cell nuclear factor-κB (NF-κB) activation and
Western blot analyses of the immunopurified apoA1 performed in nuclear localization, similarly to in vitro–oxidized lipid-free apoA1
parallel showed bands at the anticipated molecular weights of the (using the MPO-H2O2-Cl− system) or interleukin-1 (IL-1), used as
apoA1 monomer and dimer using mAb r8B5.2 or mAb 10G1.5 positive controls. In contrast to lipid-free oxTrp72-apoA1, lipid-free
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Figure 4 Characterization of oxTrp72-apoA1
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Probe: anti–oxTrp72-apoA1
recovered from human plasma. (a,b) SDS-PAGE
(mAb: r8B5.2)
followed by Coomassie Blue staining (a) or
µg per lane 20 4 4 17
µg per lane 20 4 4 17
western blot for detection of oxTrp72-apoA1
MW (kDa)
(using mAb 8B5.2) (b) of human plasma
MW (kDa)
proteins before and after buoyant density
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50
ultracentrifugation separation into the indicated
50
fractions. (c) Distribution of oxTrp72-apoA1
25
25
in the plasma. Results shown are the
mean ± s.d. of triplicate determinations of six
0
pooled healthy donor plasma pools (each pool
was obtained from at least n = 5 subjects).
(d) SDS-PAGE followed by Coomassie Blue
BAEC
Human
IP: anti–total apoA1 IP: anti–oxTrp72-apoA1
staining of immunopurified (using mAb
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polyclonal Ab lgY
mAb r8B5.2
IP: anti–oxTrp72-apoA1
r8B5.2) oxTrp72-apoA1 from plasma from
(mAb: r8B5.2)
0.50
four donors. (e) Surface VCAM1 protein
from human plasma
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expression quantified by cell-based ELISA
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* *
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(Online Methods) of bovine aortic endothelial
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cells (BAEC) incubated with plasma protein,
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*
total apoA1 (recovered from plasma using
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immobilized anti–total apoA1 IgY) or
25
oxTrp72-apoA1 (recovered from plasma using
apoA1
20
immobilized mAb r8B5.2) from 12 individual
(monomer)
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subjects. Serum-free media (SFM), HDL or
10
0
HDL previously exposed to the MPO-H2O2-Cl−
1 2 3 4
Subjects
Subjects
Subjects
system (Cl.HDL, at H2O2:apoA1, 10:1, mol:mol)
(n = 12)
(n = 12)
(n = 12)
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were used as the vehicle, negative and positive
apoA1
oxTrp72-apoA1
plasma protein
–1
–1
)
(80
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)
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(80
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controls, respectively. *P < 0.05. Results shown
are mean ± s.d. of triplicate determinations, and
IP:
IP:
P values represent comparisons between subject
anti–total
anti–
2.0
No
apoA1 oxTrp72-apoA1
samples versus SFM and were determined
hapoA1-Tg
treatment
IL-1
apoA1 ox-apoA1
IgY
mAb r8B5.2
using the Wilcoxon and Kruskal-Wallis tests.
(f) Nuclear translocation of NF-κB was
assessed by confocal immunofluorescent
1.0
analysis of BAECs, which were untreated or
treated with the following: IL-1 (positive control),
native apoA1 (apoA1), MPO-oxidized human
apoA1 (ox-apoA1), plasma-derived total apoA1
immunopurified using IgY to apoA1 or plasma
0
oxTrp72-apoA1 immunopurified using r8B5.2.
0
1
2
3
NF-κB p65 (Glu498) staining is green and
Time (d)
nuclear counterstaining (DAPI) is blue. (g) Plasma
oxTrp72-apoA1 levels were quantified at the indicated times in human apoA1 transgenic (hapoA1-Tg) mice injected i.p. with zymosan (t = 0). Quantification
was performed by sandwich ELISA using mAb r8B5.2 as the capture antibody and mAb 10G1.5 (anti–total apoA1) as the detection antibody (Online Methods).
Results shown are mean ± s.d. of triplicate determinations from n = 3 animals.
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native apoA1 isolated from plasma HDL recovered from healthy volunteers did not induce NF-κB activation (Fig. 4f).
We next investigated whether formation of oxTrp72-apoA1 is
specific to atherosclerotic plaque or if it occurs in other subacute
inflammatory conditions, such as in a peritonitis model, in which
inflammation is induced by the intraperitoneal (i.p.) injection of
yeast cell-wall protein carbohydrate components (zymosan). We have
previously shown that MPO serves as a major enzymatic catalyst for
both protein and lipid oxidation in this model35. In human apoA1
transgenic mice, formation of oxTrp72-apoA1 was readily detectable over time in both peritoneal lavage fluid (data not shown) and
plasma, demonstrating that endogenous human apoA1 is targeted for
post-translational modification at Trp72 during subacute inflammation (Fig. 4g). Thus, apoA1 may be oxidized at a local site of inflammation, such as an atherosclerosis-laden artery wall or an inflamed
peritoneal cavity, and then diffuse into the circulation.
OxTrp72-apoA1 has impaired HDL biogenesis activity in vivo
ABCA1 is critical for HDL biogenesis, and hepatocyte ABCA1
expression accounts for nearly 80% of plasma HDL production 36.

Given that MPO potently inhibits the ABCA1-dependent cholesterol efflux activity of apoA1 and HDL in vitro, and that our
site-directed mutagenesis studies support a crucial role for apoA1
Trp72 in ABCA1-dependent efflux activity (Fig. 2e), we wanted to
test whether oxTrp72-apoA1 recovered from human plasma has an
impaired capacity to stimulate HDL biogenesis in vivo. We first sought
to develop an animal model that would allow us to monitor ABCA1dependent nascent HDL particle formation in vivo. We found that
injection of lipid-free human apoA1 subcutaneously (s.c.) into apoA1
knockout (KO) mice resulted in the appearance of apoA1 in the vascular compartment (i.e., plasma), time-dependent increases in circulating HDL particle cholesterol content and incorporation of human
apoA1 into the HDL particle pool (Fig. 5a–d). To determine whether
these were ABCA1-dependent phenomena, we injected lipid-free
human apoA1 s.c. into hepatocyte-specific ABCA1 KO mice and the
appropriate ABCA1 floxed controls36. In contrast to ABCA1 floxed
control mice, where time-dependent increases in HDLc were noted
and virtually all circulating apoA1 was HDL-associated, injection
of apoA1 into ABCA1 KO mice did not result in a time-dependent
increase in plasma HDLc levels (Supplementary Fig. 5a–c).
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The fully loaded model included oxTrp72-apoA1, apoA1, age, sex, hypertension, diabetes, smoking, HDLc, circulating low-density lipoprotein (LDLc),
triglycerides, high-sensitivity C-reactive protein, hemoglobin A1C (HgbA1c), MPO and lipid lowering medicine.

i

Moreover, in ABCA1 KO mice, virtually no human apoA1 appeared
within the HDL fraction (Supplementary Fig. 5a–c).
Using this in vivo model of ABCA1-dependent HDL biogenesis, we
next tested whether oxTrp72-apoA1 recovered from human plasma
was indeed dysfunctional in vivo. Injection of apoA1 KO mice s.c.
with equivalent amounts of either lipid-free native human apoA1 or
immunoaffinity-isolated oxTrp72-apoA1 resulted in comparable timedependent appearances of total apoA1 in the circulation (Fig. 5a).
However, whereas s.c. injection of native human apoA1 induced
time-dependent increases in HDLc levels over a short period of
time (2 h), injection of oxTrp72-apoA1 did not increase HDLc levels
(despite being present in the vascular compartment), and reproducibly even slightly reduced HDLc levels (Fig. 5b). Native human apoA1
appearing in the circulation resided entirely within HDL particles
(Fig. 5c), whereas oxTrp72-apoA1 remained predominantly within
the LPD fraction (Fig. 5d). Thus, oxTrp72-apoA1 recovered from
human plasma is deficient in ABCA1-dependent HDL biogenesis
activity in vivo.
We next tested whether an apoA1 form in which Trp72 is mutated
to phenylalanine (72WF-apoA1), which is resistant to MPO-catalyzed
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oxidative inactivation in vitro (Fig. 2e), demonstrates improved biological function relative to native human apoA1 after oxidation. We
examined native wild-type recombinant human apoA1 (rh-apoA1)
and 72WF-apoA1 for in vivo HDL biogenesis activity in both their
native and MPO-oxidized forms. After s.c. injection of either the native
or oxidized forms of rh-apoA1 or 72WF-apoA1 into apoA1 KO mice,
comparable total plasma apoA1 levels were observed (Supplementary
Fig. 6a). Within 2 h after injection of native rh-apoA1, we observed
time-dependent increases in plasma HDLc levels, consistent with de
novo HDL biogenesis (Fig. 5e). In contrast, injection of rh-apoA1
exposed to the MPO-H2O2-Cl− system (apoA1:H2O2, 10:1) led to
a time-dependent decrease (within 2 h) in HDLc levels (Fig. 5e).
Injection of native 72WF-apoA1 led to a similar increase in HDLc
levels compared to native rh-apoA1, but injection of oxidized 72WFapoA1 did not lead to a reduction in HDLc levels (Fig. 5e). More
substantial differences between the behavior of rh-apoA1 and 72WFapoA1 were revealed by examination of the HDL particle distribution
of the injected apoA1 (Fig. 5f and Supplementary Fig. 6b). Whereas
most of the injected oxidized rh-apoA1 failed to become incorporated
into HDL particles, virtually all of the injected oxidized 72WF-apoA1

did so (Fig. 5f). Thus, site-specific mutation of Trp72 into the oxidantresistant residue phenylalanine produced a mutant form of apoA1
that was protected from oxidative loss of HDL biogenesis activity,
consistent with in vitro data demonstrating an improved interaction
with ABCA1 (Fig. 2e).
OxTrp72-apoA1 is abundant in human atheroma and predicts CVD
To quantify the content of oxTrp72-apoA1 in human plasma and
aortic atherosclerotic plaque homogenate, we developed a sandwich immunoassay. In this assay, mAb r8B5.2 was used as the capture antibody, and mAb 10G1.5 was used as the detection antibody
(mAb 10G1.5 recognizes native and oxidized forms of apoA1 and
HDL to comparable extents, and also recognizes lipid-free and
HDL-associated apoA1 to comparable extents). We examined
sequential consenting subjects (n = 627) undergoing elective riskfactor evaluation and cardiac examination in an outpatient preventive cardiology clinic. Examination of the clinical and demographic
characteristics of the cohort (Supplementary Table 2a) showed
that 35% of subjects had clinical evidence of CVD. Quantification
of plasma oxTrp72-apoA1 and total apoA1 levels in the cohort
revealed substantial variability among subjects. On average, only
0.007% of apoA1 in plasma harbored the 2-OH-Trp72 moiety
(Fig. 5g). In contrast, oxTrp72-apoA1 represented 20% of total
apoA1 within atherosclerotic plaque–laden aorta (n = 10) (Fig. 5g
and Supplementary Fig. 7a,b), and is thus greater than 1,000-fold
more abundant (relative to total apoA1) in plaque compared to
plasma. For illustrative purposes, we also examined plasma from a
random sampling of subjects from the cohort without (n = 8) or with
(n = 8) CVD using SDS-PAGE and either Coomassie Blue staining for
protein or western blot analyses using each of the mAbs used in the
sandwich immunoassay (Supplementary Fig. 7c–e). Of note, both
capture (mAb r8B5.2) and detection (mAb 10G1.5) antibodies in the
ELISA recognized a single major band in plasma at the molecular
weight of apoA1 monomer, although with overexposure, bands were
also notable at molecular weights corresponding to apoA1 dimer and
higher molecular weight oxidative cross-linked multimers.
Over the entire cohort, we observed the expected inverse correlations of HDLc and apoA1 levels with CAD and CVD (Supplementary
Fig. 7f–i). In contrast, the absolute concentration of oxTrp72-apoA1
and the ratio of oxTrp72-apoA1 to total apoA1 was significantly
higher in subjects with either CAD or CVD compared to their corresponding controls (i.e., non-CAD or non-CVD, respectively; Fig. 5h).
Logistic regression models with adjustment for traditional cardiac risk
factors (age, sex, hypertension, diabetes mellitus, current or former
smoker, LDLc and HDLc), triglycerides, apoA1, high-sensitivity
C-reactive protein, MPO, HbA1c and history of lipid-lowering medicine were used to estimate odds ratio and 95% confidence interval
for CVD or CAD. Higher levels of circulating oxTrp72-apoA1 (both
absolute concentration and as a ratio relative to total apoA1) were
independently associated with increased CAD and CVD risk, particularly when comparing the fourth quartile to the first (Fig. 5i and
Supplementary Table 2b). The positive associations with increased
CAD or CVD risk remained significant even after adjustments for
traditional CVD risk factors, apoA1, MPO and high sensitivity
C-reactive protein levels, and the use of lipid-lowering medication
(Fig. 5i and Supplementary Table 2b). We evaluated the improvement
in logistic regression model (Online Methods) performance introduced by the inclusion of oxTrp72-apoA1 using the net reclassification
index and the integrated discrimination improvement. Though there
was no significant gain in the area under the curve (i.e., the receiver

operating characteristic curve), inclusion of oxTrp72-apoA1 in the
fully adjusted model resulted in a significant improvement in risk estimation based on the net reclassification index (CAD: 4.1%, P < 0.001;
CVD: 5.9%, P < 0.001) and the integrated discrimination improvement (20% for both CAD and CVD, P < 0.001). Of note, the prognostic
values of HDLc and apoA1 each demonstrated the expected inverse
association with CVD and CAD risk (Fig. 5i and Supplementary
Table 2b). We also performed comparisons of the odds ratios (and
95% confidence intervals) for oxTrp72-apoA1 plasma concentration
versus traditional risk factors for CVD and found that the odds ratios
observed using oxTrp72-apoA1 concentrations as a continuous variable were comparable in magnitude to numerous established risk factors within the cohort (Supplementary Table 2c).
DISCUSSION
The atheroprotective role of HDL has been questioned because of
both recent failures of multiple HDLc-raising drugs and Mendelian
randomization studies showing that genetic variants that control
HDLc levels are not associated with risk of CAD16–18,37. Yet there
is overwhelming preclinical data showing that apoA1 has antiatherosclerotic effects1,3,5,6. This apparent contradiction has spurred
interest in better understanding the role of the HDL particle in
human CAD. Ideally, HDL in the circulation should be monitored
in a manner that reflects its function within the artery wall. Studies
thus far have shown that apoA1 recovered from human atheroma is
highly oxidized, crosslinked, dysfunctional (with respect to cholesterol efflux and LCAT activities) and lipid poor, as it is not associated
with an HDL particle25. Despite the recognition that apoA1 in lesions
is heavily oxidized, direct functional interrogation of a structurally
specific oxidative modification on apoA1 recovered from the artery
wall has not been reported, to our knowledge. Our present studies
identify the structural basis of an abundant dysfunctional form of
apoA1 and HDL within the artery wall: MPO-catalyzed site-specific
oxidation of Trp72 of apoA1 forming an oxindolyl alanine (2-OH-Trp)
moiety. We found that this form of apoA1 is highly prevalent in
human atheroma, accounting for one in five apoA1s within the lesion.
Notably, the oxidized apoA1 form oxTrp72-apoA1 was minimally
associated with HDL particles, with virtually all oxTrp72-apoA1 in
both the artery wall and plasma recovered as a lipid-poor form. Thus,
isolation of HDL-like particles recovered from human arterial lesion
homogenates using buoyant density ultracentrifugation, an approach
used by some researchers when studying apoA1 from lesions 38,39,
misses the vast majority of this abundant modified form of apoA1
in vivo. We also found that lipid-free oxTrp72-apoA1 recovered from
human plasma, like lipid-poor apoA1 modified by the MPO-H2O2-Cl−
system, is proinflammatory, capable of inducing endothelial cell NF-κB
activation and nuclear localization, as well as surface expression of
VCAM1 protein, an adhesion protein with known proatherogenic
function40. Whether differences in lipid binding capability of oxidized
as compared to native apoA1 forms contribute to pathophysiological
functions is unclear.
An overall scheme of our findings is illustrated in Figure 6a.
Circulating HDL readily diffuses into the artery wall. Within
atherosclerotic lesions, MPO is enriched and promotes site-specific
oxidative modification of apoA1 at residue Trp72. The results of
site-directed mutagenesis studies show that this residue is essential for
the ABCA1-dependent cholesterol efflux activity of apoA1 in vitro,
and animal model studies with the 72WF-apoA1 mutant demonstrate
the importance of this residue in loss of apoA1 association with
HDL particles in vivo after MPO-catalyzed oxidation. Recovery of

Figure 6 Formation of a dysfunctional apoA1 form, oxTrp72-apoA1, within
human atherosclerotic lesions. (a) Schematic summary illustrating the
formation of an abundant dysfunctional apoA1 form in human atheroma
generated by MPO (see text for details). EC, endothelial cell; SMC, smooth
muscle cell. (b) Model of spherical HDL demonstrating
the close spatial proximity between the MPO binding site on one apoA1
chain and Trp72 on the contralateral anti-parallel apoA1 chain. There are
three apoA1 chains in the reconstituted spherical HDL shown. Each chain
has a Trp72 that is in close spatial proximity to an MPO binding site on a
contralateral apoA1 chain (labels A, B and C indicate the general locations
of oxTrp and corresponding closest MPO binding site). Shown are the
longest (18 Å) and shortest (6 Å) predicted distances between oxTrp72 and
the MPO binding site on the contralateral apoA1 among the three apoA1
chains43. The apoA1 polypeptide chains are depicted in red and slate gray.
Trp72, yellow; MPO interaction site with apoA1, light blue.

apoA1 from lesions using a mAb specific for oxTrp72-apoA1
revealed virtually no detectable ABCA1-dependent cholesterol
acceptor activity and potent proinflammatory activity. Notably,
injection of apoA1 harboring the 2-OH-Trp moiety into apoA1 KO
mice con-firmed that this apoA1 form is impaired in HDL
biogenesis activity, as it failed to elicit an increase in circulating
HDLc levels or appear on HDL particles.
The MPO-H2O2-Cl− oxidative system generates a 2-oxindolyl
alanine (2-OH-Trp) moiety on apoA1 at Trp72, and our detailed
structural analyses reveal a remarkable specificity for both oxida-tion
at Trp72 and on the indole ring at the 2 position. The selective
targeting of the Trp72 site of apoA1 by the MPO system, but not by
alternative oxidation systems, appears to have a structural basis: the
close proximity between the MPO binding site on the antiparallel
apoA1 chain and Trp72 of apoA1 (Fig. 6b). It is widely believed
that apoA1 within HDL is configured predominantly as antiparallel
amphipathic alpha-helical chains27,41–45. We recently used smallangle neutron scattering with contrast variation to directly visualize
the protein shape of apoA1 within spherical HDL, the most abundant form of HDL in the circulation44. Coupled with crosslinking
mass spectrometry studies and molecular modeling, we developed a
model of apoA1 within spherical HDL44. In this model, the dis-tance
between Trp72 and the MPO binding region on apoA1, which was
identified by hydrogen-deuterium exchange (residues Ala190–
Leu203)26, is remarkably short, ranging between a maximum predicted length of 18 Å to a minimal distance of only 6 Å (Fig. 6b).
Moreover, the predicted distance between Trp72 of one apoA1 chain
and the MPO binding site on the adjacent apoA1 chain in nascent
HDL shows a similarly short distance (14 Å) (Supplementary
Fig. 8). The oxidant formed by the MPO-H2O2-Cl− system, HOCl, is
highly reactive and is scavenged rapidly by the first susceptible target
it encounters (which is virtually any amino acid, though
methionine, cysteine, histidine, tryptophan, lysine and tryosine are
the most reactive46). In all structural models of HDL reported, the
MPO binding site and Trp72 are separated by a short diffusion
distance, which probably contributes to the selective targeting of
Trp72 for oxidative modification by MPO (Fig. 6b).
Although oxTrp72-apoA1 is highly enriched within the atherosclerotic plaque, no detectable immunostaining with mAb 8B5.2 was
observed within normal aortic tissue. Thus, within the artery wall,
MPO-dependent oxidative modification of apoA1 appears to be
highly correlated with the atherosclerotic disease process. However,
we did observe an increase in circulating oxTrp72-apoA1 levels in a
mouse model of peritonitis. Thus, apoA1 may be oxidized at a local
site of inflammation, whether the artery wall or an inflamed
peritoneal cav-ity, and then diffuse into the circulation. Based on
these results, we
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would not anticipate that oxTrp72-apoA1 levels in the circulation
could serve as a specific indicator of atherosclerosis. Nonetheless,
multilogistic regression analyses within the clinical cohort examined
demonstrate that elevated levels of oxTrp72-apoA1 are associated
with CAD and CVD risk, associations that remain statistically significant after adjustments for multiple traditional risk factors,
includ-ing apoA1, MPO and other markers of inflammation. It is
possible that the proinflammatory activity of oxTrp72-apoA1 may
render it proatherogenic, such that elevated levels of oxTrp72-apoA1
may con-tribute to the well-recognized phenomenon of increased
CVD risk during chronic inflammatory conditions. However,
further studies are needed to test this intriguing hypothesis.
Our studies suggest that formation of oxTrp72-apoA1 occurs
within the protected environment of the subendothelial space (Fig.
6a), and that this oxidized form of apoA1 then diffuses out of the
artery wall to reach the intravascular compartment. MPO has been
shown to accumulate within the subendothelial compartment47 and
has been mechanistically linked to the formation of vulnerable
plaques by mechanisms including catalytic consumption of nitric
oxide48,49, activation of matrix metalloproteinase pathways50 and
promotion of endothelial cell apoptosis and superficial erosions
within culprit lesions51. Indeed, MPO is currently being examined
as a poten-tial target for functional imaging of vulnerable
plaque52,53 and as a pharmacological target for treatment of CVD.
The present studies suggest that quantification of oxTrp72-apoA1
within the circulation may serve as a gauge of proatherosclerotic
processes that impair apoA1 and HDL function in the artery wall
and that oxTrp72-apoA1 may serve as a new diagnostic and
therapeutic target in CAD.
ethods
Methods and any associated references are available in the online
version of the paper.
Note: Any Supplementary Information and Source Data files are available in the
online version of the paper.
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ONLINE METHODS

Materials. Human MPO was isolated and characterized as described54.
[3H]cholesterol was obtained from Amersham Biosciences (Piscataway, NJ).
l-[13C6]tyrosine, l-[13C9,15N1]tyrosine, [13C6,15N1]leucine, l-[13C9,15N1]
phenylalanine and l-[13C5,15N1]valine were purchased from Cambridge
Isotope Laboratories Inc. (Andover, MA). A mouse immunoglobulin isotyping
kit was obtained from GIBCO BRL (Life Technologies GmbH). Trypsin was
from Promega (Madison, WI), and all cell lines were from the American Type
Culture Collection (Rockville, MD). 5-hydroxy-l-tryptophan was purchased
from MP Biomedicals (Solon, OH). 6-hydroxyindole and 7-hydroxyindole
were purchased from Chem-Impex International Inc (Wood Dale, IL). All
peptides were synthesized by the CS Bio Company, Inc. (Menlo Park, CA).
All other reagents were obtained from Sigma-Aldrich (St. Louis, MO) unless
otherwise specified.
General procedures. All study protocols were approved by the Institutional
Review Board of the Cleveland Clinic, and all subjects gave written informed
consent. All mouse studies were performed under protocols approved by the
Institutional Animal Care and Use Committee at the Cleveland Clinic.
Circulating HDL and plasma-derived purified apoA1 were obtained from
healthy volunteer donors as previously described55. Protein content was determined by the Markwell-modified Lowry protein assay56 with BSA as the standard. Recombinant human apoA1 was generated in an Escherichia coli expression
system and isolated by sequential column chromatographies as described26,57.
Briefly, rh-apoA1 and mutants were expressed in E. coli strain BL21 (DE-3)
pLysS. All mutations were made using the QuickChange Mutagenesis Kit
(Stratagene, La Jolla, CA) and confirmed by DNA sequencing. 4WF and 4WL
represent recombinant human apoA1 in which all tryptophans (residues 8, 50,
72 and 108) were converted to phenylalanine or leucine. W8L, W50L, W72L,
W72F, W108F and W108L are recombinant human apoA1 mutants with the
indicated single tryptophan mutation. 3MV is an apoA1 mutant in which all
three methionines (at residues 86, 112 and 148) were mutated to valine. 7YF
is an apoA1 mutant in which all seven tyrosines (at residues 18, 29, 100, 115,
166, 192 and 236) were converted to phenylalanine. Reconstituted nascent
HDL was prepared using the modified sodium cholate dialysis method58 at
an initial molar ratio of 100:10:1 of POPC (1-palmitoyl-2-oleoyl-sn-glycero3-phosphocholine):cholesterol:apoA1. To remove all endotoxin from purified
recombinant apoA1, all mutants were lipidated (using POPC:apoA1, 100:1 mol:
mol), forming nascent HDL, and then delipidated by organic solvent extraction
for six consecutive rounds. Endotoxin levels in all recombinant apoA1 were
confirmed to be nominal (<0.5 EU mg−1 ml−1 protein) by Limulus amoebocyte
lysate assay (Charles River Laboratories, Wilmington, MA). The concentration
of apoA1 mutants was determined by both their predicted extinction coefficient at 280 nm and amino acid composition analyses after HCl hydrolysis (in
the pure form). The accuracy of the protein concentrations of isolated pure
apoA1 mutants was determined by stable isotope dilution LC/MS/MS analyses
on an AB SCIEX 5000 triple quadrupole mass spectrometer using synthetic
l-[13C9,15N1]tyrosine, [13C6,15N1]leucine, l-[13C9,15N1]phenylalanine and
l-[13C5,15N1]valine as internal standards and the predicted sequence of the
mutant. The concentration of H2O2 was determined spectrophotometrically
(ε240 = 39.4 M−1 cm−1). HOCl was added as NaOCl to the buffered reaction
mixtures. The concentration of NaOCl was determined spectrophotometrically
(ε292 = 350 M−1 cm−1). Peroxynitrite (ONOO−) was quantified spectrophotometrically (ε302 = 1,670 M−1 cm−1). Protein-bound ClTyr was quantified by
stable isotope dilution LC/MS/MS analyses using synthetic 3-Cl[13C6]tyrosine
and l-[13C9,15N1]tyrosine as internal standards on an AB SCIEX 5000 triple
quadrupole mass spectrometer as described26,35. Monoclonal antibodies specific for apoA1 or MPO-modified apoA1 (exposed to the MPO H2O2 Cl− or
MPO H2O2 NO2− system; H2O2:apoA1 molar ratio of 5:1) were generated using
hybridoma technology59. The cholesterol efflux (ABCA1-dependent and total)
activity of apoA1 was determined as described26. Specifically, RAW264.7 cells
(ATCC, Rockville, MD) were treated with 2 µg ml−1 of apoA1(Fig. 2b,e) or
the amount of proteins indicated in Figure 3f for 6 h. Efflux to the cholesterol
acceptor was calculated as described26. 2,3,-dioxindolyl alanine and 2-oxindoly
lalanine were synthesized as described60. Western blot quantification was done
using either ImageJ software (version 1.46, http://rsbweb.nih.gov/ij/index.html)

or Image Studio software (version 2, LI-COR Biosciences, Lincoln, NB). The
HDL-containing lipoprotein fraction (d ≤ 1.21 g ml−1) and LPD fractions
(d > 1.21 g ml−1) were recovered from plasma or tissue homogenate by sequential
buoyant density ultracentrifugation using sucrose and D2O to avoid the high
ionic strength–associated alterations to the protein composition of lipoprotein
particles observed with KBr use61. Mouse plasma (10–40 µl) was diluted to
500 µl with 1× PBS buffer (pH 7.0) and 887 µl of sucrose D2O buffer (d = 1.325
g ml−1; 0.1742 g K2HPO4, 0.1361 g KH2PO4, 0.8182 g NaCl, 111.1 g sucrose and
100 ml of D2O). The fraction with density less than 1.21 g ml−1 was obtained
after a 48-h ultracentrifugation at 40,000 r.p.m. at 20 °C (Beckman rotor 50.4Ti;
8 × 49 mm ultra-clear centrifuge tubes). The lipoprotein fraction (d ≤ 1.21 g ml−1)
was recovered by slicing the upper 0.25 ml of the tube. HDL cholesterol–
precipitating reagent (StanBIO Laboratory, 0599) was added to mouse plasma to
precipitate LDL, and HDL cholesterol was quantified by stable isotope dilution
gas chromatography mass spectrometry analyses62.
Phage display and affinity maturation of the parental antibody. A singlechain (scFv) phage display library was constructed using the cDNA derived from
the 8B5.2 hybridoma cell line using methods described by Barbas et al.63. The
murine κ variable light chain families VK1 to VK17 and the variable heavy chain
families VH1 to VH19 were amplified using 26 pairs of family-specific primers, and then the variable light chain and variable heavy chain sequences were
‘stitched’ together with a flexible linker (SSGGGGSGGGGGGSSRSS) using overlap PCR and cloned into the phagemid pCOMB3 as described63. Recombinant
phages were prepared from the library with the helper phage M13K07 at a multiplicity of infection of ~10. The library was selected using immunotubes (Costar
#3690) coated with 0.5 ml 25 µg ml−1 Cl.apoA1 (apoA1 exposed to the MPO
H2O2 Cl− system at a 10:1 molar ratio of H2O2 to apoA1) in 50 mM carbonate
buffer, pH 9.6, overnight at 4 °C (ref. 64). The rescue-selection-plating cycle
was repeated three times. For affinity maturation, another phage display scFv
library was constructed by error-prone PCR followed by passaging the library in
XL1-red mutator E. coli (Stratagene, La Jolla, CA) four times. Screening of scFv
by dissociation rate constant (Koff ) was performed using real-time biospecific
interaction analysis based on surface plasmon resonance (SPR) in a Biacore 2000
(GE Healthcare Life Sciences, Piscataway, NJ). A third library was generated
by introducing all combinations of mutant residues found in nine individual
gain-of-function clones into variable regions of the scFv gene. The scFv gene
was subcloned to a dicistronic baculoviral shuttle vector (a generous gift from
M. Liang, China CDC) and then recloned into the mammalian expression vector pcDNA3.1(+) (Life Technologies, Carlsbad, CA., catalog no. V790-20), and
the dicistronic alleles were expressed in DG44 CHO cells as a chimeric mousehuman IgG antibody.
SPR. In a Biacore flow cell, approximately 2,000 resonance units (RU) of
Cl.apoA1 (5 µg ml−1) in 10 mM sodium acetate, pH 4.5, were coupled to a
CM5 sensor chip. Association and dissociation rates of the original 8B5.2 and
recombinant affinity-matured antibody were measured under a continuous flow
of 30 ml min−1 using a concentration range from 0.7 to 1,000 nM. The Ka1
and Kd1 values were calculated using BIAeveluation software, and sensorgrams
were fitted by a bivalent model. The apparent KD was calculated from the ratio
of Kd1/Ka1.
Immunopurification of oxTrp72apoA1. Antibodies were covalently coupled to
UltraLink Hydrazide resin (Pierce Chemical Co., Rockford, IL) for immunoaffinity isolation of native or oxidized forms of apoA1 from plasma. Before immuneaffinity isolations of apoA1 forms, human albumin was first depleted from the
plasma as follows. Human plasma was dialyzed in a binding buffer (20 mM
MOPS, (MOPS: Chem-Impex International, catalog no. 00217) pH 7.0, and
100 mM NaCl) and diluted fourfold in the binding buffer before it was loaded
onto a 500-ml column bed of Q Sepharose XL resin (GE Healthcare Life Sciences,
Piscataway, NJ). Albumin-depleted plasma was collected as flow through (western blot analyses with various anti-apoA1 mAbs confirmed complete recovery of
all apoA1 forms (data not shown)). This flow-through fraction was delipidated
and, to more completely remove contaminating immunoglobulins during the
immune-affinity isolation step, reduced and denatured with guanidine hydrochloride (3 M final, pH 7.8) and dithiothreitol (1 mM final). After the denatured

fraction was incubated for 1 h at room temperature, the protein was alkylated
by the addition of iodoacetamide (2.5 mM final) and incubated for 1 h at room
temperature in a foil-wrapped container. The denatured and alkylated fraction
was dialyzed against 20 mM Tris-Cl and 150 mM NaCl, and oxTrp72-apoA1 was
purified from this solution using a covalently coupled r8B5.2 affinity column.
Total apoA1 was similarly purified using a covalently coupled chicken polyclonal
IgY that recognizes total apoA1 (anti-HDL IgY microbead slurry; catalog no.
A20088-G100; Genway Biotech, San Diego, CA).
Cell surface VCAM1 protein expression. Cell surface VCAM1 protein levels
were determined in BAECs (bovine aortic endothelial cells, Lonza Walkersville,
Walkersville, MD, catalog no. AC-6001T25). BAECs were starved in DMEM for
4 h and then incubated with 80 µg of protein per ml of HDL or 80 µg of protein
per ml of HDL exposed to the MPO H2O2 Cl– system (Cl.HDL) or, where
indicated, individual protein and plasma for 16 h. After one wash with PBS,
the cells were fixed in 4% paraformaldehyde for 20 min and blocked in 0.5%
casein in PBS with 0.02% NaN3 for 4 h. Surface VCAM1 protein was determined
using goat polyclonal anti-VCAM1 primary antibody (1:4,000, sc-1504, Santa
Cruz Biotechnology, Santa Cruz, CA) with anti-goat IgG antibody conjugated
with horseradish peroxidase (1:5,000, sc-2020, Santa Cruz Biotechnology, Santa
Cruz, CA) as a secondary antibody, detection by SureBlue tetramethylbenzidine
peroxidase substrate (KPL Inc., Gaithersburg, MD) and measuring absorbance
at 450 nm on a 96-well plate reader (Spectramax 384 Plus, Molecular Devices,
Sunnyvale, CA) after the addition of 1 M HCl to stop the reaction.
Confocal immunofluorescent analysis. BAECs (2 × 104 cells per well) were
inoculated into Lab-Tek Chamber 16-well glass slides (Electron Microscopy
Sciences, Hatfield, PA) for 16 h. The cells were treated with drugs (Fig. 4f),
80 µg ml−1 each at 37 °C for 20 min. The cells were then washed with PBS and
fixed with 4% paraformaldehyde in PBS (15 min, room temperature), permeabilized by immersion in 0.5% Triton X-100 (10 min, room temperature), quenched
with 100 mM glycine (10 min, room temperature) and blocked in 1% BSA and
10% normal goat serum in PBS, pH 7.0 (1 h at room temperature). Blocked cells
were incubated sequentially with primary antibody to NF-κB p65 (Glu498) (3987,
Cell Signaling Technology, Danvers, MA) diluted (100-fold) in blocking buffer
(overnight, 4 °C) and secondary antibody goat anti-rabbit IgG-FITC (ab6717-1,
Abcam, Cambridge, MA) diluted in blocking buffer (100:1, 1 h, room temperature). Coverslips were mounted onto glass slides using Vectashield DAPI mounting medium (Vector Laboratories Inc., Burlingame, CA). Images were viewed on
a Leica DMRXE confocal microscope (Leica Microsystems Inc, Buffalo Grove,
IL) using a 63× oil-immersion objective with a 1.40 numeric aperture. Confocal
images were acquired using the Leica Confocal Software Version 2.61.
Immunochemistry staining of atherosclerotic plaques. Fresh human aortic
tissue was obtained as discarded surgical material, both at time of organ harvest
from transplant donors, and during valve and aortic arch (‘elephant trunk’)
replacement surgery. Immunohistochemistry of atherosclerotic plaques and
normal aorta was carried out on fresh-frozen sections. The anti-oxTrp72apoA1
antibody (r8B5.2 Fab) and polyclonal rabbit anti-human MPO (A0398, Dako
North America, Inc., Carpinteria, CA) were used at a dilution of 1:400. Mouse
normal IgG1 (X0931, Dako North America, Inc., Carpinteria, CA) (diluted 400:1)
was used as the control for antibody staining. The staining procedure followed
the protocol of the DakoCytomation Envision+ system HRP(AEC) (Dako North
America, Inc., Carpinteria, CA).
Aortic tissue homogenization. At the time of harvest, all tissues were immediately rinsed in ice-cold PBS supplemented with 100 µM diethylenetriamine
pentaacetic acid (DTPA) and frozen at −80 °C in argon-sparged buffer A (65 mM
sodium phosphate, pH 7.4, 100 µM DTPA and 100 µM butylated hydroxytoluene) in gas-tight containers overlaid with argon, which were kept within larger
argon-flushed sealed containers. At the time of use, samples sealed in gas-tight
containers were placed in an ice and water bath. Immediately before being complete thawed, tissues were rinsed five times with ice-cold argon-sparged Ca2+ and
Mg2+-free PBS supplemented with 100 µM DTPA to remove any residual visible
hemoglobin. The aorta segment was rapidly cleaned of fatty tissues and placed in
a Petri dish containing ice-cold PBS. The adventitial layer and outer portion of

the media were carefully peeled from the vessel to give a clean smooth aorta. The
aorta was rinsed with ice-cold PBS three times and the wet weight of the aorta
was determined. The tissue was then cut into small pieces (about 3 to 5 mm in
diameter) in a Petri dish cover on ice. Tissue pieces were suspended in ice-cold
Ca2+ and Mg2+-free PBS containing a protease inhibitor cocktail. The protease
cocktail PMSF (1 mM) and Sigma-Aldrich protease inhibitor cocktail (P8340)
were included in all subsequent solutions used for lipoprotein isolation. Aortic
tissue was homogenized on ice with a Polytron Tissue Homogenizer (Model PT
10/35, Brinkman Instruments Inc., Westbury, NY) for 1 min followed by five
30-s intervals in an ice and water bath. The homogenate was then centrifuged
at 12,000g for 30 min. The pellet was discarded and the supernatant was stored
on ice until use. HDL and LPD fractions were separated by ultracentrifugation
using a sucrose and D2O protocol61.
Indirect ELISA. Nunc MaxSorp ELISA plates (#446612, Thermo Fisher
Scientific, Waltham, MA) were coated with the indicated purified native or
oxidized protein (0.2 µg ml−1) in carbonate and bicarbonate buffer, pH 9.6.
Purified human apoA1, rh-apoA1 and mutant apoA1s were modified by the
MPO H2O2 Cl− system, the MPO H2O2 NO2− system or multiple other oxidation
systems, as indicated, at a 10:1 molar ratio of oxidants and apoA1, unless otherwise specified (the details of the oxidation conditions are described in ref. 25).
The primary antibody r8B5.2 (50 ng ml−1) (Figs. 1d and 2a,e) was added into the
5% BSA–blocked ELISA wells and incubated for 1 h at room temperature. The
plates were then washed with PBS and 0.05% Tween 20 (PBST) four times. Signal
was detected by Peroxidase AffiniPure Goat Anti-Mouse IgG, F(ab′)2 Fragment
Specific (1:10,000, code 115-036-006, Jackson ImmunoResearch Laboratories,
Inc., West Grove, PA).
Competitive ELISA. Nunc MaxSorp ELISA plates (#446612, Thermo Fisher
Scientific, Waltham, MA) were coated with 0.5 µg ml−1 Cl.apoA1 in carbonate
and biocarbonate buffer, pH 9.6 (human apoA1 modified by the MPO H2O2 Cl−
complete oxidative system at a 10:1 molar ratio of H2O2 and apoA1). r8B5.2
(25 ng ml−1) and peptides were added into the 5% BSA–blocked ELISA wells and
incubated for 1 h at room temperature. The signal was detected by Peroxidase
AffiniPure Goat Anti-Mouse IgG, F(ab′)2 Fragment Specific (1:10,000, code
115-036-006, Jackson ImmunoResearch Laboratories, Inc., West Grove, PA).
Sandwich ELISA. Costar ELISA plates (#3690) were coated with capture
antibody r8B5.2 (50 µl per well, 7 µg ml−1 in 0.1 M Tris-Cl, pH 8.5) at 4 °C
overnight. Except for the capture antibody coating process, all other reactions
were performed at room temperature (20 °C). Coated plates were washed with
PBS buffer twice, and then washed plates were blocked with 170 µl of blocking
buffer (1% fish peptone (Fluka Biochemika, 93490), 3% BSA (Sigma, A7030),
2% poly vinyl alcohol and 0.05% Tween 20 in PBS, pH 7.4) for 2 h. A calibration
curve was constructed with Cl.apoA1 (8 pM to 8 nM) in sample dilution buffer
(1% salmon serum and 0.05% Tween 20 in PBS, pH 7.4). Pooled plasma samples
that had been aliquoted into single-use samples were thawed once and used as
controls on every plate. Plasma samples were diluted in sample dilution buffer
(1% salmon serum and 0.05% Tween 20 in PBS, pH 7.4). Diluted samples were
added into the blocked EIA wells at 50 µl per well and incubated for 45 min.
The plates were then washed with PBST four times. The detection mAb 10G1.5
(anti-total apoA125) was diluted (1:40,000) in antibody dilution buffer (0.03%
BSA (Sigma, A7030) in PBST) and incubated in an EIA well at 50 µl per well for
30 min. After four washes with PBST, horseradish peroxidase–conjugated neutravidin (31001, Pierce Chemical Co., Rockford, IL; 1:10,000 diluted in antibody
dilution buffer) was added into the ELISA plates (50 µl per well) and incubated
for 30 min. The ELISA was developed with SureBlue TMB substrate (#52-00-0,
KPL, Gaithersburg, MD) and the OD450 was determined.
Research subjects. Multiple healthy volunteers donated blood for isolation of
apoA1, HDL, MPO and other human-derived plasma proteins used throughout the course of these studies. To examine the relationship between levels
of oxTrp72-apoA1 and prevalence of CAD and CVD, a cohort of sequential
consenting subjects (n = 627) presenting to the preventive cardiology outpatient clinic of the Cleveland Clinic was examined as part of an observational
study called BioBank. Fasting plasma samples and associated clinical data were

collected at time of patient visit. The CAD definition included adjudicated
diagnoses of stable or unstable angina, myocardial infarction, angiographic
evidence of >50% stenosis of one or more major epicardial vessels or history
of coronary revascularization. Peripheral artery disease (PAD) was defined
as any evidence of extracoronary atherosclerosis or ankle brachial index <0.9.
Atherosclerotic CVD was defined as the presence of either CAD or PAD. Patients
who had experienced a myocardial infarction or stroke within the 1 month
preceding enrollment were ineligible.
Mouse models. Breeders of all conventional mice C57BL/6 (catalog no. 000664),
apoA1 homozygous transgenic (catalog no. 001927, C57BL/6-Tg(APOA1)1Rub/J)
and ApoA1–/– mice (B6.129P2-Apoa1tm1Unc, catalog no. 002055) were obtained
from Jackson Laboratories. Control mice have a floxed ABCA1 gene (Abca1flox/flox).
Hepatocyte-specific ABCA1 knockout (Abca1−L/−L; Alb-Cre) Apoa1–/– mice
on a C57BL/6 background have been described36,65. In our previous study36,
we documented that wild-type (+/+) and Abca1flox/flox mice have a similar plasma
lipid phenotype. For the subacute peritonitis model, apoA1 homozygous transgenic animals were injected i.p. with zymosan. Plasma was obtained at baseline
before injection and then serially (1, 2 and 3 d) after injection. OxTrp72-apoA1
levels in plasma were measured by sandwich ELISA using mAb r8B5.2 as the
capture antibody and mAb 10G1.5 (anti-total apoA125) as the detection antibody. To examine the role of hepatocyte ABCA1 in de novo HDL biogenesis
in vivo after apoA1 injection, control mice (Abca1flox/flox) and hepatocytespecific ABCA1 KO mice (6–7 weeks old) (Abca1−L/−L; Alb-Cre ) were injected
with the indicated form of apoA1 s.c. at 400 mg per kg body weight. Blood was
collected by saphenous vein puncture 1 week before apoA1 injection (baseline)
and 0.5 h, 1 h, 1.5 h and 2 h after apoA1 injection. ApoA1 KO mice were similarly
injected s.c. with the indicated form of apoA1 at 400 mg per kg body weight,
and the appearance and distribution of total human apoA1 and oxTrp72-apoA1
levels in the blood were monitored both at baseline and 2 h after apoA1 injection.
All experiments were performed with female mice.
Statistical analyses. Data are presented as the median (first quartile–third
quartile) for continuous measures and as a number (percentage) for categorical
measures. Student’s t test or Wilcoxon rank-sum test for continuous variables
and χ2 test for categorical variables were used to examine the differences

between participants who had cardiovascular disease events and those who did
not. Logistic regression models with adjustment for traditional Framingham
cardiac risk factors (age, sex, hypertension, diabetes mellitus, current or former
smoker, LDLc and HDLc), triglycerides, apoA1, high sensitivity C-reactive
protein, MPO, HgbA1c and history of lipid-lowering medicine were used to
estimate odds ratio and 95% confidence interval for CVD or CAD. All analyses
were performed using R 2.15.0 (Vienna, Austria), and P < 0.05 was considered
statistically significant.
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